When Tetrionics, a rapidly growing pharmaceutical outsourcing company, gained FDA approval to produce a new drug, they retained Strang to design and build a new facility meeting rigorous drug manufacturing regulations - all within 12 months.

The new 25,000-s.f. headquarters provide more than 10 times as much office, laboratory and production space as Tetrionics' previous space. The facility was designed with amenities to attract new personnel, and retain the existing workforce.

GMP laboratories support production of chemically produced Active Pharmaceutical Ingredients (API's) and early-stage drug development. These laboratories feature built-in flexibility to accommodate the changing focus of the drug development business, while a sophisticated air-handling system minimizes contamination. A pilot plant supports large-scale production to respond to Tetrionics' outsourcing partners' need for greater capacity. This production capacity allows the firm to establish relationships with partners from pre-clinical studies through commercial development.

Additional building components include a glass wash area and separate spaces for compound preparation, chemical quarantine and storage, research and development, quality control, regulatory compliance, and complex mechanical equipment. The facility also has administrative, sales and marketing offices, as well as shipping and receiving.